|
Market Price |
Recommendation |
Target |
Time Horizon |
|
707.90 |
Buy |
890 |
1-Year |
Amrutanjan Health Care Limited reported net revenue of ₹113.75 crores for the quarter ended September 30, 2022, compared to ₹114 crores for September 30, 2021. Profit After Tax was ₹12.76 crores for the quarter ended September 30, 2022, compared to ₹19.85 crores during the corresponding quarter of the previous year, respectively.
STOCKDATA
|
52 Week H/L |
688/954.60 |
|
Market Cap (crores) |
2,069 |
|
Face Value (₹) |
1.00 |
|
Book Value |
90.70 |
|
EPS TTM |
23.00 |
|
NSE Code |
AMRUTANJAN |
Amrutanjan was founded in Mumbai as a patent medicine business. Amrutanjan changed its name to Amrutanjan Limited in 1936 and became a public limited corporation. Amrutanjan Limited was replaced by Amrutanjan Healthcare Limited on November 13, 2007.
The company has 2,363 distributors, 613 suppliers, 647 employees, and 1.19 million outlets (Rubefacient).
SHAREHOLDING PATTERN(%)
|
|
Mar-22 |
June-22 |
Sep-22 |
|
Promoter |
50.02 |
50.02 |
50.02 |
|
Public |
42.23 |
42.21 |
42.62 |
|
FII |
1.43 |
1.42 |
0.87 |
|
DII |
6.14 |
6.16 |
6.30 |
|
OTHERS |
0.18 |
0.18 |
0.18 |

Beta: 0.39 |
Alpha: 7.23 |
Risk Reward Ratio:1.45 |
Margin of Safety:20% |
Shri K. Nageswara Rao Pantulu Garu established the company in 1893 as a patent medicine company in Bombay. Amrutanjan Pain Balm, the company's flagship product, was introduced.
Amrutanjan Health Care Limited, one of the top OTC companies in India, is renowned for offering products that promote speedy and natural recovery by fusing the natural principles of Ayurveda with contemporary technology.
The Company entered the field of pain management for the first time in 1893 with its iconic yellow balm, which quickly became the standard treatment for headaches and aches.
Since then, the company has grown into other industries, including those related to essentials like beverages, congestion management, women's health, and cleanliness. The resilient product line offered by the company consists of:
Amrutanjan pain balms and roll-ons.
Advanced body range products such as roll-ons, musclespray, and pain patches.
Cold & congestion products such as Relief cold rub, nasal inhalers, and cough syrup.
Beverages such as fruit-based rehydration drink - Fruitnik Electro+ and fruit juice - Fruitnik fruit drink.
Women’s hygiene product, Comfy Snug Fit sanitary Napkins.
Other essentials such as AmrutanjanDecorn corn caps, Amrutanjan No Germs hand sanitisers and Amrutanjan Stop Pain dental gel.
The fact that all of the items in its pain treatment category are all-natural and free of artificial substances like diclofenac demonstrates the company's commitment to encouraging healthful living.
Additionally, the company set up its own non-surgical pain management centre to address chronic pain and other conditions.
In 2011, the company introduced the "Comfy" brand after seeing how little menstrual health and cleanliness are known in India. Its current position as India's fourth-largest sanitary napkin brand by volume share demonstrates the company's dedication to the introduction of reasonably priced, high-quality goods.
Following are the reporting operations of the company:
OTC Products:
Manufacturing products for pain management, congestion management, and hygiene.
Beverages:
Manufacturing fruit juices and oral rehydration drinks.
Others:
Pain management center.
Revenue contribution from OTC products was 91.71%, Beverages was 7.86%, and from others was 0.43% in FY 2022 compared to 94.42%, and 0.45% in FY 2021, respectively.
Geographically contribution from India was 98% and from countries were 2% in FY 2022 compared to 98% and 2% in FY 2021, respectively.




STRENGTH
Net debt-free company.
Strong financial performance.
The company hasa legacy of over 110 years.
Diversified product portfolio.
WEAKNESS
Decline quarterly net profit with a falling profit margin.
Trading below 52-week low.
Limited pricing flexibility because of intense competition.
OPPORTUNITIES
An established market position and strong brand recall in the pain management segment will help the company to maintain its stake in a related sector.
THREAT
Increasing global uncertainty.
An increase in prices of raw materials costs could impact the profit of the company.


Global civilizations have embraced the ancient science and treatment system known as ayurveda. After analysing a person's body type, heartbeat rhythms, appearance, vision, and other characteristics, Ayurveda diagnoses and treats illnesses.
The ayurveda system offers several protocols and therapies to treat illnesses through the use of plants, herbs, exercise, food, and lifestyle changes.
Oral care, skincare, make-up, hair care, and fragrances are the market segments for personal care products. The market for ayurvedic nutraceuticals, ayurvedic medicines, and dietary supplements is divided into the healthcare category. Companies throughout the nation are concentrating on creating cutting-edge ayurvedic products and raising consumer awareness.
An important element influencing the market for ayurvedic products in India is the growing consumer acceptance of natural and organic medications and the advantages they offer.
Ayurvedic products are now much more easily accessible in both urban and rural areas because of an improved distribution network. The Indian government is pushing the use of ayurvedic products through subsidies and awareness campaigns.
The market for ayurvedic products in India was worth ₹515.5 billion in 2021, and it is anticipated that the market would grow at a CAGR of 19.78% from 2022 to 2027 to reach ₹1,536.9 billion.
There are around 53000 MSMEs in the Ayush industry, according to data on the Udyam portal (Micro - 47,892; Small - 4,412; Medium - 719). Ayush is one of the top five health services with Medical Value Travel (MVT) in India according to export revenues for health services.
|
Quarterly (INR in lakhs) |
Sep-22 |
Jun-22 |
Mar-22 |
Dec-21 |
Sep-21 |
|
Revenue from Operations |
11,071.93 |
7,095.42 |
10,655.30 |
11,069.59 |
11,038.20 |
|
Other income |
303.24 |
301.25 |
516.02 |
319.83 |
428.51 |
|
Total Income |
11,375.17 |
7,396.67 |
11,171.32 |
11,389.42 |
11,466.71 |
|
|
|||||
|
Total Expenditure |
9,631.16 |
6,869.18 |
9,166.31 |
8,594.94 |
8,824.19 |
|
EBIT |
1,744.01 |
527.49 |
2,005.01 |
2,794.48 |
2,642.52 |
|
|
|||||
|
Finance cost |
1.95 |
2.44 |
3.08 |
2.98 |
6.91 |
|
EBT before Exceptional Items |
1,742.06 |
525.05 |
2,001.93 |
2,791.50 |
2,635.61 |
|
|
|||||
|
Exceptional Items |
- |
- |
- |
- |
- |
|
PBT |
1,742.06 |
525.05 |
2,001.93 |
2,791.50 |
2,635.61 |
|
|
|||||
|
Tax Expenses |
465.56 |
158.65 |
531.34 |
733.72 |
650.83 |
|
PAT |
1,276.50 |
366.40 |
1,470.59 |
2,057.78 |
1,984.78 |
|
|
Mar-19 |
Mar-20 |
Mar-21 |
Mar-22 |
|
Revenue from Operations |
25,322.73 |
26,147.67 |
33,284.40 |
40,584.24 |
|
Other Income |
713.09 |
832.13 |
1,132.01 |
1,538.25 |
|
Total Income |
26,035.82 |
26,979.80 |
34,416.41 |
42,122.49 |
|
|
|
|
|
|
|
Cost of Goods sold |
11,886.85 |
11,707.12 |
`14,018.52 |
18,046.25 |
|
Gross Profit |
14,148.97 |
15,272.68 |
20,397.89 |
24,076.24 |
|
|
|